Clinical trials

16

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder

This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a single oral dose of VQW-765 compared to placebo in adults with social anxiety disorder.

Participants needed: 500
Trial details
Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Vanda PharmaceuticalsUpdated: Jun 25, 2026Locations: 31
Eligibility criteria

Ability and willingness to provide written informed consent. [+5]

Suicide attempts and/or suicidal ideation in the past 2 years or currently at ri... [+7]

Status: Recruiting

Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis

An open label study to investigate the safety and efficacy of ponesimod in participants with moderate-to-severe chronic plaque psoriasis

Participants needed: 300
Trial details
Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Vanda PharmaceuticalsUpdated: Jun 11, 2026Locations: 4
Eligibility criteria

Male and female subjects aged 18-65 years, inclusive [+5]

Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), gut... [+1]

Status: Recruiting

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female pediatric participants with insomnia disorder.

Participants needed: 420
Trial details
Phase: Phase 3Age: 2-17Biological sex: AllType: InterventionalSponsor: Vanda PharmaceuticalsUpdated: Jun 5, 2026Locations: 35
Eligibility criteria

Ability and acceptance to provide written informed consent of the participant or... [+3]

Inability to dose daily with tasimelteon or previous intolerance to tasimelteon. [+3]

Status: Recruiting

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

The goal of this study is to measure the effects of using Tradipitant to treat nausea and vomiting induced by GLP-1R agonist use in adults with class I or class II obesity, or adults who are overweight with at least one weight-related condition. The study is placebo-controlled with two treatment arms.

Participants needed: 280
Trial details
Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Vanda PharmaceuticalsUpdated: Apr 20, 2026Locations: 10
Eligibility criteria

Body Mass Index ≥ 25 and < 40 kg/m² [+1]

Another disorder that contributes to gastrointestinal symptoms [+3]

Status: Recruiting

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

The aim of this study is to investigate the safety and tolerability of trichostatin A in individuals with relapsed or refractory hematologic malignancies.

Participants needed: 42
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Vanda PharmaceuticalsUpdated: Mar 16, 2026Locations: 11
Eligibility criteria

Subject is ≥ 18 years at the time of signing informed consent; [+4]

Allogeneic stem cell transplant recipient presenting with graft versus host dise... [+5]

Status: Recruiting

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

Participants needed: 240
Trial details
Phase: Phase 2Age: 18-65Biological sex: AllType: InterventionalSponsor: Vanda PharmaceuticalsUpdated: Feb 27, 2026Locations: 28
Eligibility criteria

SiSBP >/= 130 mmHg despite >8 weeks treatment w/ 1 or more antihypertensive ther...

Confirmed Grade 3/severe hypertension (SiSBP >/= 180 mmHg, SiDBP >/= 120 mmHg),...

Status: Recruiting

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder

The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder

Participants needed: 500
Trial details
Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Vanda PharmaceuticalsUpdated: Feb 27, 2026Locations: 38
Eligibility criteria

Male or female patient 18 to 65 years of age, inclusive; [+2]

Within the patients lifetime, has a confirmed DSM-5-TR psychiatric diagnosis oth... [+2]

Status: Recruiting

Randomized Withdrawal Study in Patients With Schizophrenia

The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

Participants needed: 400
Trial details
Phase: Phase 3Age: 18-65Biological sex: AllType: InterventionalSponsor: Vanda PharmaceuticalsUpdated: Jan 12, 2026Locations: 22
Eligibility criteria

Males or females 18 to 65 years of age (inclusive) [+2]

DSM-5 diagnosis of a psychiatric disorder other than schizophrenia that was the...

Status: Recruiting

Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)

This is a multicenter, double-blind, randomized study to evaluate the efficacy and safety of a daily single oral dose of tasimelteon and matching placebo in male and female participants with DSWPD.

Participants needed: 70
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Vanda PharmaceuticalsUpdated: Dec 2, 2025Locations: 17
Eligibility criteria

Ability and acceptance to provide written informed consent. [+3]

Exacerbation of an existing psychiatric condition that requires change in treatm... [+4]

Status: Recruiting

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.

Participants needed: 160
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Vanda PharmaceuticalsUpdated: Sep 17, 2025Locations: 5
Eligibility criteria

Be at least 18 years of age of either gender and any race. [+2]

Use of any of the disallowed medications during the washout and study period.

Status: Available

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

Primary Objective: To treat a single patient with gastroparesis who has requested expanded access with tradipitant

Trial details
Age: 18-70Biological sex: AllType: Expanded AccessSponsor: Vanda PharmaceuticalsUpdated: Aug 24, 2025Locations: 15
Eligibility criteria

Identified subject who requested expanded access [+4]

Another active disorder or treatment which could explain or contribute to sympto... [+4]

Status: Recruiting

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

To evaluate the safety and tolerability of iloperidone in adolescent patients with schizophrenia or bipolar I disorder for up to 52 weeks of treatment.

Participants needed: 100
Trial details
Phase: Phase 4Age: 12-17Biological sex: AllType: InterventionalSponsor: Vanda PharmaceuticalsUpdated: Mar 4, 2025Locations: 9
Eligibility criteria

Patient is willing and able to provide assent and willing to complete all aspect... [+3]

Use of other investigational drugs at the time of enrollment, or within 30 days... [+1]

Status: Recruiting

Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis

This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.

Participants needed: 100
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Vanda PharmaceuticalsUpdated: Feb 20, 2025Locations: 3
Eligibility criteria

Diagnosed with gastroparesis [+3]

Another active disorder or treatment which could explain or contribute to sympto... [+3]

Status: Recruiting

Evaluating the Effects of Tasimelteon Vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) and the CRY1Δ11 Variant

This is a double-blind, randomized, two-period crossover study to evaluate the efficacy and safety of a single oral dose of tasimelteon and matching placebo in male and female subjects with DSWPD and the CRY1Δ11 variant.

Participants needed: 60
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Vanda PharmaceuticalsUpdated: Nov 22, 2024Locations: 1
Eligibility criteria

Ability and acceptance to provide written informed consent. [+4]

Major surgery, trauma, illness, general anesthesia, or immobility for 3 or more... [+3]

Status: Recruiting

Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances

This database will be used to better understand the sleep problems of people with SMS. This clinical database will be a part of a larger Smith-Magenis Patient Registry used to create an awareness campaign around SMS and the sleep disturbances that are characteristic of the disorder.

Participants needed: 1,000
Trial details
Age: 3-65Biological sex: AllType: ObservationalSponsor: Vanda PharmaceuticalsUpdated: Mar 20, 2024Locations: 1
Eligibility criteria

Parent or legal guardian of individual with Smith-Magenis Syndrome

Not legal guardian of individual with SMS

Status: Recruiting

Patient Registry of Blind Subjects With Sleep-related Problems

Non-24-hour sleep-wake disorder (Non-24) is a condition experienced primarily by totally blind individuals that results in abnormal night sleep patterns and chronic daytime sleepiness. This is a research protocol to develop a patient registry of subjects who may suffer from Non-24 and who are blind. Subjects participate in the study through a phone survey. This registry will be used to better understand, sleep related problems in blind individuals, including the investigation of a potential treatment, recruitment for future clinical studies, and to provide a forum for raising awareness about Non-24. The survey consists of questions regarding the degree of vision impairment and sleep problems that the subjects may be experiencing.

Participants needed: 10,000
Trial details
Biological sex: AllType: ObservationalSponsor: Vanda PharmaceuticalsUpdated: Jun 24, 2020Locations: 1
Eligibility criteria

Subjects or legal guardians must be at least 18 years of age to participate in t... [+2]